OZEM provides exposure to the rapidly growing
weight loss management market, which is expected to reach
$100 billion by 2030.
NEW
YORK, May 21, 2024 /PRNewswire/ -- Roundhill
Investments, an ETF sponsor focused on innovative financial
products, is pleased to announce the launch of the Roundhill GLP-1
& Weight Loss ETF (OZEM), which began trading on Nasdaq today.
OZEM is the world's first ETF focused exclusively on the rapidly
growing sector of GLP-1 receptor agonists and other weight
management drugs.
"OZEM offers investors a unique opportunity to efficiently
access the companies leading the charge against the global obesity
epidemic," said Dave Mazza, CEO of
Roundhill Investments. "With obesity rates nearly tripling since
1975 and projected to affect over half the population by 2035, the
market for weight loss drugs is in its early stages, offering
substantial growth potential for companies pioneering innovation in
the space."
The obesity treatment market is set for explosive growth.
Goldman Sachs Research forecasts that the market could expand by
more than 16 times its current size to reach $100 billion by 2030.2
The Roundhill GLP-1 & Weight Loss ETF (OZEM) is an
actively-managed ETF that is designed to provide exposure to a
global portfolio of companies involved in developing weight loss
therapeutics.
The fund's top holdings include:
HOLDINGS
|
%
WEIGHTING
|
Eli Lilly &
Co
|
20.16 %
|
Novo Nordisk
A/S
|
19.90 %
|
Innovent Biologics
Inc
|
4.59 %
|
Zealand Pharma
A/S
|
4.57 %
|
Chugai Pharmaceutical
Co Ltd
|
4.47 %
|
Amgen Inc
|
4.24 %
|
Altimmune
Inc
|
4.19 %
|
Viking Therapeutics
Inc
|
3.50 %
|
Terns Pharmaceuticals
Inc
|
3.41 %
|
Structure Therapeutics
Inc
|
3.24 %
|
Holdings are subject to change. Data as of 5/20/24.
1 WHO, Global Health Observatory (2022),
Ourworldindata.com, 2 Goldman Sachs Global Investment
Research; Company data.
About Roundhill Investments
Founded in 2018, Roundhill Investments is an SEC-registered
investment advisor focused on innovative exchange-traded funds.
Roundhill's suite of ETFs offers unique and differentiated
exposures across thematic equity, options income, and trading
vehicles. Roundhill offers a depth of ETF knowledge and experience,
as the team has collectively launched more than 100+ ETFs including
several first-to-market products.
Investors should consider the investment objectives, risk,
charges and expenses carefully before investing. For a prospectus
or summary prospectus with this and other information about
Roundhill ETFs please call 1-855-561-5728 or visit the website at
www.roundhillinvestments.com/etf/OZEM. Read the prospectus or
summary prospectus carefully before investing.
Health Care Companies Risk. Health care companies, such
as companies providing medical and healthcare goods and services,
companies engaged in manufacturing medical equipment, supplies and
pharmaceuticals, as well as operating health care facilities and
the provision of managed health care, may be affected by government
regulations and government health care programs, increases or
decreases in the cost of medical products and services and product
liability claims, among other factors. Many health care companies
are heavily dependent on patent protection, and the expiration of a
company's patent may adversely affect that company's profitability.
Health care companies are also subject to competitive forces that
may result in price discounting, may be thinly capitalized and
susceptible to product obsolescence.
Pharmaceutical Companies Risk. The Fund may have
significant exposure to pharmaceutical companies in connection with
its investments in GLP-1 & Weight Loss Companies.
Pharmaceuticals companies may be affected by industry competition,
dependency on a limited number of products, obsolescence of
products, government approvals and regulations, loss or impairment
of intellectual property rights and litigation regarding product
liability. Pharmaceutical are subject to competitive forces that
may make it difficult to raise prices of their products and may
result in price discounting. The profitability of some
pharmaceuticals companies may be dependent on a relatively limited
number of products. The research and development costs required to
bring a new product to market are substantial with no guarantee
that the product will ever become profitable. Many new products are
subject to gaining the approval of the U.S. Food and Drug
Administration ("FDA"), which can be long and costly. Many
pharmaceutical companies are heavily dependent on patents and
intellectual property rights. The loss or impairment of these
rights may adversely affect the profitability of these companies.
Pharmaceuticals companies may also be subject to extensive
litigation based on product liability and similar claims.
Biotechnology Companies Risk. The Fund may have
significant exposure to biotechnology companies in connection with
its investments in GLP-1 & Weight Loss Companies. Biotechnology
companies invest heavily in research and development which may not
necessarily lead to commercially successful products. Biotechnology
companies are subject to increased governmental regulation which
may delay or inhibit the release of new products. The effects of
high development costs and increased regulation may be exacerbated
by a company's inability to raise prices to cover costs because of
managed care pressure or price controls. Many biotechnology
companies are dependent upon their ability to use and enforce
intellectual property rights and patents. Any impairment of such
rights may have adverse financial consequences. Biotechnology
stocks, especially those issued by smaller, less-seasoned
companies, tend to be more volatile than the overall market.
Biotechnology companies can also be significantly affected by
technological change and obsolescence, product liability lawsuits
and consequential high insurance costs.
Concentration Risk. The Fund is concentrated in the
industry or group of industries comprising the health care sector.
The Fund may be susceptible to an increased risk of loss, including
losses due to adverse events that affect the Fund's investments
more than the market as a whole, to the extent that the Fund's
investments are concentrated in the securities and/or other assets
of a particular issuer or issuers, country, group of countries,
region, market, industry, group of industries, sector, market
segment or asset class.
New Fund Risk. The Fund is a recently organized
investment company with a limited operating history. As a result,
prospective investors have a limited track record or history on
which to base their investment decision.
Roundhill Financial Inc. serves as the investment advisor. The
Funds are distributed by Foreside Fund Services, LLC which is not
affiliated with Roundhill Financial Inc., U.S. Bank, or any of
their affiliates.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/roundhill-investments-launches-glp-1--weight-loss-etf-ozem-302150664.html
SOURCE Roundhill Investments